East Windsor, NJ, United States of America

Chongqing Sun

This inventor holds 25 USPTO granted patents and 2 EPO patents, primarily in Cannabinoid Receptor Modulators. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2003-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chongqing Sun. Retrieved from https://idiyas.com/inventor/chongqing-sun

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 25

% Patents Active = 96.0

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 4.0

ph-index = 6

Forward Citations = 128(Granted Patents)

Company Filing History:

25 out of 3,746

Bristol-Myers Squibb Compnay

patents

Years Active: 2003-2018

Loading Chart...

Areas of Expertise:

GPR40 Modulators

Adipic Acid Amides

Diaminocyclohexane

Triazolopyridine

Cannabinoid Receptor

Bicyclic Heterocycles

Fused Cyclic Succinimide

Androgen Receptor

Pyrazole Derivatives

Tetrahydroquinoline

Pyrazine Modulators

Nuclear Hormone Receptor

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10017497 - Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes (2018-07-10),

2. 9346852 - Substituted adipic acid amides and uses thereof (2016-05-24),

3. 8815909 - Diaminocyclohexane compounds and uses thereof (2014-08-26),

4. 8710049 - Diaminocyclohexane compounds and uses thereof (2014-04-29),

5. 8394823 - Triazolopyridine compounds useful as DGAT1 inhibitors (2013-03-12),

6. 8324241 - Triazolo compounds useful as DGAT1 inhibitors (2012-12-04),

7. 8119808 - Tetrahydroquinoline derivatives as cannabinoid receptor modulators (2012-02-21),

8. 7884113 - Tetrahydroquinoline derivatives as cannabinoid receptor modulators (2011-02-08),

9. 7858639 - Bicyclic heterocycles as cannabinoid-1 receptor modulators (2010-12-28),

10. 7816357 - Azabicyclic heterocycles as cannabinoid receptor modulators (2010-10-19),

11. 7709647 - Tetrahydroquinoline cannabinoid receptor modulators (2010-05-04),

12. 7655688 - Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function (2010-02-02),

13. 7632837 - Bicyclic heterocycles as cannabinoid-1 receptor modulators (2009-12-15),

14. 7625923 - Bicyclic modulators of androgen receptor function (2009-12-01),

15. 7572808 - Triazolopyridine cannabinoid receptor 1 antagonists (2009-08-11),

Title: Chongqing Sun: Innovator and Inventor Extraordinaire

Introduction:

Chongqing Sun, based in East Windsor, NJ, has established an impressive track record throughout his career as an innovator and inventor. His dedication to pushing boundaries and his ability to transform data into groundbreaking solutions have earned him numerous accolades and recognition within the industry.

Latest Patents:

Chongqing Sun's latest patents showcase his profound expertise in medical science and pharmaceutical innovation. Two notable patents are:

1. Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes:

This patent covers compounds that act as GPR40 G protein-coupled receptor modulators, suitable for use as medicaments. These compounds have the potential to revolutionize the treatment of diseases like diabetes. They are formulated following a specific chemical composition, designated by Formula (I) or its derivatives.

2. Substituted adipic acid amides and uses thereof:

This patent involves compounds that act as agonists, partial agonists, and/or modulators of the NPY4 receptor. These compounds, represented by Formula (I) or its derivatives, exhibit promising potential for treating and preventing obesity, food intake regulation, and other conditions influenced by the NPY4 receptor.

Career Highlights:

Over the course of his career, Chongqing Sun has achieved remarkable milestones and received several prestigious awards. Recognizing his outstanding contributions to the field of innovation, he has been honored with prominent distinctions such as the Inventor of the Year Award and the Technology Innovator Award. These accolades serve as a testament to his groundbreaking work and commitment to advancing scientific knowledge.

Collaborations:

Chongqing Sun has successfully collaborated with notable individuals within his field. Two of his esteemed coworkers include William R Ewing and Yanting Huang. These collaborations have not only enhanced Sun's own innovative capabilities but have also contributed to the broader scientific community's knowledge and advancement.

Conclusion:

Chongqing Sun's exceptional career, spanning multiple accomplishments and renowned patents, exemplifies his innovative spirit and unwavering dedication to scientific progress. Through his groundbreaking work in pharmaceuticals and medical science, he continues to pave the way for advancements that positively impact human health and well-being. Chongqing Sun's contributions to the field are a testament to his relentless pursuit of innovation and solidify his status as a distinguished figure in the world of inventions and patents.

Profile summary based on public USPTO records.